Kinam Hong

Senior Investment Advisor

2014 - 2015

Generation and Long-Term Fundamental Research: Developed investment ideas by leveraging 20 years of proprietary experience and background in healthcare sector Expertise in industry and company specific due diligence, including scientific, product pipeline and market opportunity assessment, competitive analysis and key healthcare trends for making result-driven investment decisions Other key areas of value added experience and advisory services related to investment decision making and portfolio management: Clinical (product development and strategy) Regulatory (Regulatory path and strategy) Commercial (business development/M&A, commercial strategy, pricing/reimbursement, competitive/market analysis) Analysis of investment decision making process Portfolio risk management

Co-Fund Manager/Portfolio Manager

2011 - 2013

Fund Strategy: Managed a fundamental, long-term oriented investment portfolio in a global equity fund with focus on biotechnology in U.S., Europe and Asia Activist Investing: Played important role in strategy and operations of portfolio companies through active dialogue with senior management

Senior Investment Manager

2009 - 2011

Value and Growth Focused Fundamental Research: Performed rigorous, valuation and product focused analysis of undervalued companies or companies with significant growth potential Stock Picking and Investment Strategy: Conducted deep, fundamental due diligence of biotech/pharma companies with focus on oncology, cardiovascular, neurological and infectious diseases

Research Analyst

2006 - 2009

Stock Initiations and Coverage: Led initiation of stock coverage by conducting company due diligence, competitive analysis, and management interviews; managed coverage of 30 companies by publishing proprietary research, managing financial models and making rating recommendations Citigroup Top Five Junior Analyst Honor (2007 and 2008)

Senior Manager

2003 - 2006

New Product Development/Strategy: Guided HIV vaccine commercialization through Phase III testing; justified no-go decision of a developmental vaccines in the pipeline Business Development: Performed technical and business due diligence; evaluated multiple biotherapeutic deals Key Market Strategy: Defined Sanofi-Aventis’ business and strategy within the context of public health policy system in China and developed a plan of action based on the results

Resident Physician

1999 - 2001